In a recent press release, Tru-D SmartUVC, which was recently validated by the first and only randomized clinical trial on UV disinfection, announced that they will attend and exhibit at APIC 2017, June 14-16 in Portland, Oregon.
Each year, APIC delivers the largest annual conference of infection preventionists from across the U.S., and Tru-D invites the more than 2,500 attendees to stop by their booth #808.
“The recently-published Benefits of Enhanced Terminal Room-Disinfection study proves that Tru-D can cut the transmission of four major superbugs by a cumulative 30 percent,” said Chuck Dunn, CEO and president of Tru-D SmartUVC. “We look forward to sharing the study results with APIC attendees and demonstrating how Tru-D can help hospitals build comprehensive UV disinfection programs that mimic the study’s outcomes.”
Tru-D offers a programmatic approach to standardizing UV implementation and utilization in acute care settings and surgical suites. Tru-D’s Director of Clinical Affairs, Ralph Taylor, RN, MSN, MHA, CNOR, has nearly two decades of health care experience including several years spent as Director of Surgical Services at Oak Hill Hospital in Florida. His expertise in successfully implementing UV strategies led to a significant decrease in HAIs in the hospital with minimal disruption to workflow. In addition, Tru-D’s Director of Program Management, Cathy Campbell, CMIP, has more than 20 years of experience in the development and implementation of Environmental Services programs. She has contributed to product innovations, infection prevention support, sustainability efforts and technical training for Environmental Services specifically within health care. Together, they, along with the entire Tru-D team, offer an expert-led approach that is built on science and drives results.